Lazapir (Olanzapine)

Olanzapine works by blocking dopamine D2 receptors and serotonin 5‑HT2A receptors, which moderates neurotransmission linked to psychosis and mood disturbances. Its additional activity at histamine, muscarinic and adrenergic receptors contributes to its overall therapeutic profile, helping to stabilize mood and reduce hallucinations or delusions.

The appropriate dose of Lazapir is individualized by the prescribing clinician based on the patient’s diagnosis, severity of symptoms, prior treatment response, age, liver function and any concomitant medications. Dosage adjustments are made according to clinical response and tolerability, following local prescribing guidelines.

Safety data for olanzapine in pregnancy are limited; it should only be used when the potential benefit outweighs any risk to the fetus. During breastfeeding, olanzapine can be excreted in breast milk, so a risk‑benefit assessment is required. Healthcare providers should discuss alternatives and monitoring strategies with the patient.

To order Lazapir, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lazapir (olanzapine) is known for strong efficacy in controlling both psychotic and manic symptoms, but it is also associated with a higher propensity for metabolic side effects such as weight gain and glucose elevation compared with some other atypicals. Choice of therapy depends on individual patient factors, efficacy needs and tolerability considerations.

Lazapir should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from excess moisture, light and heat. Do not store in bathrooms or near windows where temperature fluctuations may occur.

Lazapir is taken orally, usually as a tablet or other solid oral dosage form, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include neuroleptic malignant syndrome, agranulocytosis, severe hyperglycemia, tardive dyskinesia, seizures and myocarditis. Patients should be monitored for fever, muscle rigidity, sudden changes in blood counts, blood sugar spikes, involuntary movements or cardiac symptoms, and seek immediate medical attention if they occur.

Lazapir is contraindicated in individuals with known hypersensitivity to olanzapine or any of its excipients. Caution is advised for patients with uncontrolled diabetes, severe cardiovascular disease, a history of neuroleptic malignant syndrome, or those taking medications that strongly interact with olanzapine metabolism.